13 results on '"Hirose, Toyoki"'
Search Results
2. Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS)
- Author
-
Ahmed, Khlood, Arima, Yuichiro, Tabata, Noriaki, Ishii, Masanobu, Sato, Ryota, Yamashita, Takayoshi, Yamanaga, Kenshi, Takizawa, Hitoshi, Hokimoto, Seiji, Sueta, Daisuke, Araki, Satoshi, Fujisue, Koichiro, Takashio, Seiji, Fujimoto, Kazuteru, Shimomura, Hideki, Tsunoda, Ryusuke, Hirose, Toyoki, Sato, Koji, Kikuta, Koichi, Sakaino, Naritsugu, Nakamura, Shinichi, Yamamoto, Nobuyasu, Matsumura, Toshiyuki, Kajiwara, Ichiro, Tayama, Shinji, Sakamoto, Tomohiro, Nakao, Koichi, Oshima, Shuichi, Yamamoto, Eiichiro, Sakamoto, Kenji, Kaikita, Koichi, Matsushita, Kenichi, and Tsujita, Kenichi
- Published
- 2022
- Full Text
- View/download PDF
3. Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study
- Author
-
Sakamoto, Kenji, Sato, Ryota, Tabata, Noriaki, Ishii, Masanobu, Yamashita, Takayoshi, Nagamatsu, Suguru, Motozato, Kota, Yamanaga, Kenshi, Hokimoto, Seiji, Sueta, Daisuke, Araki, Satoshi, Fujisue, Koichiro, Arima, Yuichiro, Takashio, Seiji, Fujimoto, Kazuteru, Shimomura, Hideki, Tsunoda, Ryusuke, Hirose, Toyoki, Sato, Koji, Kikuta, Koichi, Sakaino, Naritsugu, Nakamura, Shinichi, Yamamoto, Nobuyasu, Matsumura, Toshiyuki, Kajiwara, Ichiro, Tayama, Shinji, Sakamoto, Tomohiro, Nakao, Koichi, Oshima, Shuichi, Yamamoto, Eiichiro, Kaikita, Koichi, and Tsujita, Kenichi
- Published
- 2022
- Full Text
- View/download PDF
4. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.
- Author
-
Takashio, Seiji, Tokitsu, Takanori, Matsukawa, Masakazu, Sakaino, Naritsugu, Fujimoto, Kazuteru, Sakamoto, Tomohiro, Noda, Katsuo, Tsunoda, Ryusuke, Misumi, Ikuo, Hirai, Nobutaka, Doi, Hideki, Koide, Shunichi, Mizuno, Yuji, Hirose, Toyoki, Kurokawa, Hirofumi, Kajiwara, Ichiro, Ohba, Keisuke, Miyamoto, Shinzo, Araki, Satoshi, and Yamamoto, Eiichiro
- Abstract
• The epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) is not yet understood in Japan. • We conducted a retrospective multicenter observational cohort study in Kumamoto. • The incidence of ATTR-CM was about 1 per 10,000 person-years in the elderly. • Age at diagnosis was older in the regional hospitals than referral facilities. • Possible ATTR-CM was more frequent in the regional hospital cohort. In recent years , transthyretin amyloid cardiomyopathy (ATTR-CM) has received increasing attention; however, the epidemiology of ATTR-CM in Japan is not yet understood. In the Kumamoto Cardiac Amyloid Survey, we evaluated the current incidence, clinical characteristics, diagnostic approaches, and treatment strategies for ATTR-CM and compared tafamidis-prescription hospitals with regional hospitals. We conducted a retrospective multicenter observational cohort study. The registry included patients with ATTR-CM diagnosed in two tafamidis-prescription hospital institutes [Japanese Circulation Society (JCS)-certified facilities] and 15 regional cardiovascular facilities in Kumamoto between January 2018 and December 2020. In total, 174 patients were diagnosed with ATTR-CM. The incidence of ATTR-CM was estimated to be approximately 1 per 10,000 person-years in the elderly population (>65 years old) in Kumamoto. Compared with that in the JCS-certified facilities cohort (n=115), age at diagnosis was significantly older (84.5 ± 5.6 vs. 77.5 ± 6.3 years old; p <0.01) in the regional hospitals cohort (n=59). Histological (25% vs. 81%; p <0.01) and genetic diagnosis (7% vs. 82%) were also less frequently performed. Probable (as indicated by positive bone scintigraphy findings with confirmation of monoclonal protein absence) and possible (as indicated by positive bone scintigraphy findings without confirmation of monoclonal protein absence) ATTR-CM accounted for the majority of cases (75% vs. 19%; p <0.01) in the regional hospitals cohort compared to the JCS-certified facilities cohort. There were no cases of hereditary ATTR-CM among the patients who underwent TTR genetic testing (n=98). We confirmed the incidence of ATTR-CM in Kumamoto and the diagnostic approach used in patients with ATTR-CM. Further prospective studies with a larger sample are needed to validate our results and to further shed light on the epidemiology of ATTR-CM in Japan. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Clinical outcomes of percutaneous coronary intervention (PCI) at hospital with or without onsite cardiac surgery backup
- Author
-
Akasaka, Tomonori, Hokimoto, Seiji, Oshima, Shuichi, Nakao, Koichi, Fujimoto, Kazuteru, Miyao, Yuji, Shimomura, Hideki, Tsunoda, Ryusuke, Hirose, Toyoki, Kajiwara, Ichiro, Matsumura, Toshiyuki, Nakamura, Natsuki, Yamamoto, Nobuyasu, Koide, Shunichi, Oka, Hideki, Morikami, Yasuhiro, Sakaino, Naritsugu, Kaikita, Koichi, Nakamura, Sunao, Matsui, Kunihiko, and Ogawa, Hisao
- Published
- 2014
- Full Text
- View/download PDF
6. Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases – INVITATION trial.
- Author
-
Fujisue, Koichiro, Shirakawa, Takuhiro, Nakamura, Shinichi, Yamamoto, Nobuyasu, Oshima, Shuichi, Matsumura, Toshiyuki, Tsunoda, Ryusuke, Hirai, Nobutaka, Tayama, Shinji, Nakamura, Natsuki, Hirose, Toyoki, Maruyama, Hideki, Fujimoto, Kazuteru, Kajiwara, Ichiro, Sakamoto, Tomohiro, Nakao, Koichi, Sakaino, Naritsugu, Hokimoto, Seiji, Nagayoshi, Yasuhiro, and Hokamaki, Jun
- Abstract
Background Acute myocardial infarction (AMI) is mainly characterized by the rupture of lipid-rich vulnerable atherosclerotic plaque. The matrix metalloproteinases (MMPs) have been shown to play a critical role in inflammatory processes underlying plaque rupture. Some reports suggested statins inhibit the increased MMP levels after AMI. However, there are a few comparison studies between the different dosages of the same statin and circulating levels of MMPs. Purpose This study will preliminarily investigate the potential effects of appropriate or low dose of rosuvastatin on circulating MMPs levels in AMI patients. Moreover, we will also obtain plasma from patients while undergoing diagnostic angiography to determine differences in various cardiac sites and peripheral vessels. Methods This study is a multicenter, open-label, randomized, parallel-group study to be conducted to compare the appropriate or low dose of rosuvastatin in the effect on serum levels of inflammatory markers in AMI patients. The eligible patients undergoing percutaneous coronary intervention (PCI) will be randomly assigned to receive either appropriate or low-dose rosuvastatin daily using a web-based randomization software within 24 h after PCI. The low-dose group will be treated with rosuvastatin 2.5 mg once daily with a follow-up. The appropriate-dose group will begin treatment with rosuvastatin 5 mg once daily, and the dose of rosuvastatin will be titrated to 10 mg within 4 weeks. During administration of the study treatment, subjects will undergo laboratory testing including MMPs and be monitored for the occurrence of adverse events up to 24 weeks. The primary endpoint will be the change rate of MMPs at 24 weeks after administration. Conclusions INVITATION will compare the appropriate or low dose of rosuvastatin in the effects on serum levels of inflammatory markers including MMPs in AMI patients. This study will provide significant information on rosuvastatin as an anti-inflammatory agent for AMI. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup.
- Author
-
Akasaka, Tomonori, Hokimoto, Seiji, Sueta, Daisuke, Tabata, Noriaki, Oshima, Shuichi, Nakao, Koichi, Fujimoto, Kazuteru, Miyao, Yuji, Shimomura, Hideki, Tsunoda, Ryusuke, Hirose, Toyoki, Kajiwara, Ichiro, Matsumura, Toshiyuki, Nakamura, Natsuki, Yamamoto, Nobuyasu, Koide, Shunichi, Nakamura, Shinichi, Morikami, Yasuhiro, Sakaino, Naritsugu, and Kaikita, Koichi
- Abstract
Background Based on the 2011 American College of Cardiology/American Heart Association percutaneous coronary intervention (PCI) guideline, it is recommended that PCI should be performed at hospital with onsite cardiac surgery. But, data suggest that there is no significant difference in clinical outcomes following primary or elective PCI between the two groups. We examined the impact of with or without onsite cardiac surgery on clinical outcomes following PCI for acute coronary syndrome (ACS). Methods and results From August 2008 to March 2011, subjects ( n = 3241) were enrolled from the Kumamoto Intervention Conference Study (KICS). Patients were assigned to two groups treated in hospitals with ( n = 2764) or without ( n = 477) onsite cardiac surgery. Clinical events were followed up for 12 months. Primary endpoint was in-hospital death, cardiovascular death, myocardial infarction, and stroke. And we monitored in-hospital events, non-cardiovascular deaths, bleeding complications, revascularizations, and emergent coronary artery bypass grafting (CABG). There was no overall significant difference in primary endpoint between hospitals with and without onsite cardiac surgery [ACS, 7.6% vs. 8.0%, p = 0.737; ST-segment elevation myocardial infarction (STEMI), 10.4% vs. 7.5%, p = 0.200]. There was also no significant difference when events in primary endpoint were considered separately. In other events, revascularization was more frequently seen in hospitals with onsite surgery (ACS, 20.0% vs. 13.0%, p < 0.001; STEMI, 21.9% vs. 14.5%, p = 0.009). We performed propensity score matching analysis to correct for the disparate patient numbers between the two groups, and there was also no significant difference for primary endpoint (ACS, 8.6% vs. 7.5%, p = 0.547; STEMI, 11.2% vs. 7.5%, p = 0.210). Conclusions There is no significant difference in clinical outcomes following PCI for ACS between hospitals with and without onsite cardiac surgery backup in Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Abstract 14566: Impact of Silent Myocardial Ischemia on One Year Mortality After Successful Coronary Intervention: Data From Japanese Multicenter (KICS) Registry.
- Author
-
Motozato, Kota, Sakamoto, Kenji, Yamashita, Takayoshi, Nagamatsu, Suguru, Sato, Ryota, Hokimoto, Seiji, Oshima, Shuichi, Nakao, Koich, Fuijimoto, Kazuteru, Miyao, Yuji, Shimomura, Hideki, Tsunoda, Ryusuke, Maruyama, Hideki, Hirose, Toyoki, Sueta, Daisuke, Araki, Satoshi, Arima, Yuichiro, Nakamura, Sunao, Kaikita, Koichi, and Tsujita, Kenichi
- Published
- 2018
9. Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial.
- Author
-
Shirakawa T, Fujisue K, Nakamura S, Yamamoto N, Oshima S, Matsumura T, Tsunoda R, Hirai N, Koide S, Tayama S, Kikuta K, Hirose T, Maruyama H, Fujimoto K, Kajiwara I, Sakamoto T, Nakao K, Sakaino N, Nagayoshi Y, Hokamaki J, Shimomura H, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Ogawa H, and Tsujita K
- Subjects
- Aged, Cohort Studies, Dose-Response Relationship, Drug, Female, Humans, Japan, Male, Middle Aged, Percutaneous Coronary Intervention, Time Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Matrix Metalloproteinase 2 blood, Matrix Metalloproteinase 9 blood, Myocardial Infarction blood, Myocardial Infarction therapy, Rosuvastatin Calcium administration & dosage
- Abstract
Aim: Matrix metalloproteinases (MMPs) play critical roles in acute myocardial infarction (AMI). This trial was conducted to determine the potential effects of higher-dose rosuvastatin on circulating MMP levels in patients with AMI., Methods: This was a multicenter, open-label, 1:1 randomized, parallel-group study. Patients with AMI were randomly assigned to the appropriate-dose group (10 mg rosuvastatin once daily) or the low-dose group (2.5 mg rosuvastatin once daily) within 24 hours after percutaneous coronary intervention. MMP-2 and MMP-9 levels were measured on day 1 and at week 4, 12, and 24 after enrollment. The primary endpoint was the change in MMP levels at 24 weeks after enrollment. The secondary endpoints were change in MMP levels at day 1 and weeks 4 and 12 after enrollment., Results: Between August 2017 and October 2018, 120 patients with AMI from 19 institutions were randomly assigned to either the appropriate-dose or the low-dose group. There were 109 patients who completed the 24-week follow-up. The primary endpoint for both MMP-2 and MMP-9 was not significantly different between the two groups. The change in the active/total ratio of MMP-9 at week 12 after baseline was significantly lower in the appropriate-dose group compared with the low-dose group (0.81 [-52.8-60.1]% vs. 70.1 [-14.5-214.2]%, P=0.004), while the changes in MMP-2 were not significantly different between the two groups during the study period., Conclusions: This study could not demonstrate the superiority of appropriate-dose of rosuvastatin in inhibiting serum MMPs levels in patients with AMI.
- Published
- 2022
- Full Text
- View/download PDF
10. Prognostic Value of the CHADS 2 Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation-A Multi-Center Observational Cohort Study.
- Author
-
Tabata N, Yamamoto E, Hokimoto S, Yamashita T, Sueta D, Takashio S, Arima Y, Izumiya Y, Kojima S, Kaikita K, Matsui K, Fujimoto K, Sakamoto K, Shimomura H, Tsunoda R, Hirose T, Nakamura N, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Koide S, Sakamoto T, Nakao K, Oshima S, and Tsujita K
- Subjects
- Aged, Aged, 80 and over, Cerebrovascular Disorders diagnosis, Cerebrovascular Disorders mortality, Coronary Artery Disease diagnosis, Coronary Artery Disease mortality, Coronary Artery Disease therapy, Female, Humans, Japan, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction diagnosis, Myocardial Infarction mortality, Percutaneous Coronary Intervention, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Registries, Risk Assessment, Risk Factors, Time Factors, Cerebrovascular Disorders etiology, Coronary Artery Disease complications, Decision Support Techniques, Myocardial Infarction etiology
- Abstract
Background: The CHADS
2 score has mainly been used to predict the likelihood of cerebrovascular accidents in patients with atrial fibrillation. However, increasing attention is being paid to this scoring system for risk stratification of patients with coronary artery disease. We investigated the value of the CHADS2 score in predicting cardiovascular/cerebrovascular events in coronary artery disease patients without atrial fibrillation., Methods and Results: This was a multicenter, observational cohort study. The subjects had been admitted to one of the participating institutions with coronary artery disease requiring percutaneous coronary intervention. We calculated the CHADS2 scores for 7082 patients (mean age, 69.7 years; males, 71.9%) without clinical evidence of atrial fibrillation. Subjects were subdivided into low- (0-1), intermediate- (2-3), and high-score (4-6) groups and followed for 1 year. The end point was a composite of cardiovascular/cerebrovascular death, nonfatal myocardial infarction, and ischemic stroke at 1-year follow-up. Rates of triple-vessel/left main trunk disease correlated positively with CHADS2 score categories. CHADS2 scores among single, double, and triple-vessel/left main trunk groups were 2 (1-2), 2 (1-3), and 2 (2-3), respectively ( P <0.001). A total of 194 patients (2.8%) had a cardiovascular/cerebrovascular event, and Kaplan-Meier analysis demonstrated a significantly higher probability of cardiovascular/cerebrovascular events in proportion to a higher CHADS2 score (log-rank test, P <0.001). Multivariate Cox hazard analysis identified CHADS2 score (per 1 point) as an independent predictor of cardiovascular/cerebrovascular events (hazard ratio, 1.31; 95% CI, 1.17-1.47; P <0.001)., Conclusions: This large cohort study indicated that the CHADS2 score is useful for the prediction of cardiovascular/cerebrovascular events in coronary artery disease patients without atrial fibrillation., (© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.)- Published
- 2017
- Full Text
- View/download PDF
11. Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation - The Kumamoto Intervention Conference Study (KICS) Registry.
- Author
-
Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Matsui K, and Ogawa H
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Cardiovascular Diseases complications, Cardiovascular Diseases epidemiology, Cardiovascular Diseases surgery, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic etiology, Renal Insufficiency, Chronic prevention & control, Stents adverse effects
- Abstract
Background: The aim of this study was to examine the effects of different statins on the clinical outcomes of Japanese patients with coronary stent implants., Methods and Results: This study included 5,801 consecutive patients (males, 4,160; age, 69.7±11.1 years, mean±SD) who underwent stent implantation between April 2008 and March 2011. They were treated with a strong statin (n=3,042, 52%, atorvastatin, pitavastatin, or rosuvastatin), a regular statin (n=1,082, 19%, pravastatin, simvastatin, or fluvastatin) or no statin (n=1,677, 29%). The patients with chronic kidney disease (CKD) were divided into mild-to-moderate CKD (30≤eGFR<60, n=1,956) and severe CKD (eGFR <30, n=559). Primary endpoints included cardiovascular death and nonfatal myocardial infarction, including stent thrombosis and ischemic stroke. The clinical outcome for the primary endpoint in mild-to-moderate CKD patients treated with a strong statin (hazard ratio 0.50, 95% confidence interval 0.31-0.81; P=0.005) was significantly lower than in those on no statins, but that in the patients treated with a regular statin was not (P=0.160). The clinical outcome for the primary endpoint in severe CKD patients treated with a strong or regular statin was no different than not being on statin therapy (P=0.446, P=0.194, respectively)., Conclusions: In patients with mild-to-moderate CKD, only strong statins were associated with lower risk compared with no statin, but regular statins were not. It is possible that taking a strong statin from the early stage of CKD is useful for suppression of cardiovascular events.
- Published
- 2015
- Full Text
- View/download PDF
12. A survival case of cardiogenic shock due to left main coronary artery myocardial infarction: successful cooperation with on-site percutaneous coronary intervention and helicopter emergency medical service.
- Author
-
Kimura Y, Ohba K, Sumida H, Tsujita K, Hirose T, Maruyama H, Hirai S, Kaikita K, Hokimoto S, Sugiyama S, and Ogawa H
- Subjects
- Coronary Angiography, Electrocardiography, Humans, Intra-Aortic Balloon Pumping, Male, Middle Aged, Myocardial Infarction diagnostic imaging, Shock, Cardiogenic diagnostic imaging, Treatment Outcome, Air Ambulances, Myocardial Infarction complications, Myocardial Infarction therapy, Percutaneous Coronary Intervention, Shock, Cardiogenic etiology, Shock, Cardiogenic therapy
- Abstract
A 54-year-old man was referred to a local hospital, located about 90 km from our hospital, with cardiogenic shock due to left main coronary artery infarction (LMCA-MI). Percutaneous coronary intervention (PCI) was performed under intra-aortic balloon pumping (IABP) support, but resulted in insufficient reperfusion and his condition worsened. The helicopter emergency medical service (HEMS) rapidly transported the patient to our hospital. After percutaneous cardio-pulmonary support system (PCPS) insertion, PCI could establish the coronary flow. A series of intensive therapies saved the patient. The cooperation of medical and emergency service system following revascularization and intensive care saved the patient with LMCA-MI accompanied by cardiogenic shock.
- Published
- 2012
- Full Text
- View/download PDF
13. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
- Author
-
Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Maruyama H, Hirose T, Yamamoto K, Mizobe M, Kaikita K, Nakamura S, and Ogawa H
- Subjects
- Aged, Aged, 80 and over, Aspirin therapeutic use, Clopidogrel, Female, Follow-Up Studies, Heartburn epidemiology, Hematemesis epidemiology, Humans, Incidence, Japan, Male, Middle Aged, Myocardial Infarction epidemiology, Platelet Aggregation Inhibitors therapeutic use, Proton Pump Inhibitors adverse effects, Registries, Retrospective Studies, Stroke epidemiology, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, Treatment Outcome, Angioplasty, Balloon, Coronary methods, Asian People ethnology, Coronary Disease ethnology, Coronary Disease therapy, Proton Pump Inhibitors therapeutic use, Stents
- Abstract
Background: The aim of this study was to examine the effect of proton-pump inhibitor (PPI) on clinical outcomes in Japanese patients who undergo coronary stent implantation., Methods and Results: A total of 1,270 patients (males 915, 69 years) were enrolled and dual antiplatelet therapy of aspirin and a thienopyridine derivative was prescribed (clopidogrel 630, ticlopidine 640). Patients were divided into 2 groups treated with or without PPI. PPI was administered in 331 cases (26%), and non-PPI in 939 (74%). There were no significant differences in cardiovascular death (PPI vs. non-PPI: 5 vs. 11 cases), nonfatal myocardial infarction (3 vs. 5), and stroke (3 vs. 16) between PPI and non-PPI groups, but the ratio of gastrointestinal events had a higher tendency in non-PPI group compared with PPI group (1 vs. 17, P=0.08). In subgroup analysis of patients taking clopidogrel, or patients with acute coronary syndrome, there was no significant difference in the ratio of cardiovascular events (7 vs. 16, 6 vs. 17, NS). The non-PPI group had a tendency of an increased risk of gastrointestinal events compared with the PPI group (0 vs. 9, P=0.06; 1 vs. 7, P=0.14)., Conclusions: In contrast to the negative drug interaction of PPI reported elsewhere, in the present study the intake of PPI was not associated with an increased risk for adverse clinical outcomes in patients treated with stents.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.